Celltrion Accelerates Antibody, Kit Development As It Takes Coronavirus Initiative
Urges Other Large Firms To Join Effort
Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.
You may also be interested in...
Helped by government support for the development of COVID-19 drugs and vaccines, Celltrion’s monoclonal antibody becomes the first therapeutic for the disease to be officially approved in South Korea.
Join Jung Won Shin, Brian Yang and Ian Haydock in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series, COVID-19: Lessons Learned And A Path Forward.
South Korea authorities talk to foreign media about the country's experience and successes in dealing with the COVID-19 situation, lessons learned, preparations being made to return to everyday life and R&D activity.